Moreover, decorin competes with the natural ligand of EGFR, the epidermal growth factor (EGF), and the decorin-EGFR interaction results in internalization and degradation of the receptor via caveolar endocytosis (120), thus controlling tumor growth (121–123). The gene discussed is EGFR; the disease is neoplasm.